Classical conditioning of antidepressant placebo effects in mice.


Journal

Psychopharmacology
ISSN: 1432-2072
Titre abrégé: Psychopharmacology (Berl)
Pays: Germany
ID NLM: 7608025

Informations de publication

Date de publication:
Jan 2020
Historique:
received: 18 02 2019
accepted: 09 08 2019
pubmed: 20 8 2019
medline: 5 6 2020
entrez: 19 8 2019
Statut: ppublish

Résumé

Placebo effects in human clinical trials for depression treatment are robust and often comparable to drug effects. Placebo effects are traditionally difficult to study in rodents due to the slow-onset action of classical antidepressant drugs. We hypothesized that the rapid antidepressant actions of ketamine would allow modeling antidepressant placebo effects in rodents. Male and female CD-1 mice received either ketamine or saline injections with concomitant exposure to specific environmental conditioning stimuli, for a total of three drug/conditioning sessions each 2 weeks apart. Two weeks later, during an evocation phase, mice were exposed to the drug-paired conditioning stimuli or no conditioned stimuli followed by testing for motor stimulatory actions and antidepressant-like effects using the forced swim test. Negative (no ketamine administration at any time) and positive (acute ketamine administration prior to evocation testing) control groups were included as comparators. Both male and female mice exhibited increased locomotor activity following ketamine administration during the conditioning phase, which was not observed following exposure to the conditioning stimuli. Exposure to the conditioning stimuli previously paired with ketamine, similar to an acute ketamine administration, reduced immobility time in the forced swim test both 1 and 24 h after administration in male, but not female, mice. These results represent the first evidence of antidepressant-like placebo-conditioned effects in an animal model. The developed approach can be used as a model to explore the neurobiological mechanisms of placebo effects, their possible sexually dimorphic effects, and relevance to mechanisms underlying antidepressant action.

Identifiants

pubmed: 31422429
doi: 10.1007/s00213-019-05347-4
pii: 10.1007/s00213-019-05347-4
pmc: PMC6954278
mid: NIHMS1537687
doi:

Substances chimiques

Antidepressive Agents 0
Ketamine 690G0D6V8H

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

93-102

Subventions

Organisme : BLRD VA
ID : I01 BX004062
Pays : United States
Organisme : NIMH NIH HHS
ID : R01 MH107615
Pays : United States
Organisme : U.S. Department of Veterans Affairs
ID : 1I01BX004062
Organisme : NIMH NIH HHS
ID : MH107615
Pays : United States

Références

Am J Psychiatry. 2002 May;159(5):728-37
pubmed: 11986125
Int Rev Neurobiol. 2018;138:1-15
pubmed: 29681320
Psychosom Med. 2008 Sep;70(7):811-8
pubmed: 18725424
Mol Psychiatry. 2018 Oct 3;:null
pubmed: 30283029
Int J Neuropsychopharmacol. 2013 May;16(4):849-56
pubmed: 22827928
Pain. 2014 Oct;155(10):2022-32
pubmed: 25026214
Br J Psychiatry. 2001 Mar;178:192-4
pubmed: 11230026
Science. 2010 Aug 20;329(5994):959-64
pubmed: 20724638
J Pain. 2014 Dec;15(12):1282-93
pubmed: 25261340
Nature. 2011 Jun 15;475(7354):91-5
pubmed: 21677641
Am J Psychiatry. 2013 Oct;170(10):1134-42
pubmed: 23982301
Pharmacol Biochem Behav. 1995 Jun-Jul;51(2-3):291-6
pubmed: 7667342
JAMA. 2010 Jan 6;303(1):47-53
pubmed: 20051569
Pain. 2013 Apr;154(4):511-4
pubmed: 23473783
Biol Psychiatry. 2008 Feb 15;63(4):349-52
pubmed: 17643398
Lancet Psychiatry. 2016 Nov;3(11):1059-1066
pubmed: 27726982
Psychopharmacology (Berl). 2011 Jun;215(3):537-48
pubmed: 21384106
J Neurosci. 2005 Nov 9;25(45):10390-402
pubmed: 16280578
Annu Rev Pharmacol Toxicol. 2019 Jan 6;59:191-211
pubmed: 30216744
Mol Psychiatry. 2017 May;22(5):656-665
pubmed: 28322276
Arch Gen Psychiatry. 2006 Aug;63(8):856-64
pubmed: 16894061
Synapse. 2008 Sep;62(9):682-8
pubmed: 18566972
Am J Psychiatry. 2016 Aug 1;173(8):816-26
pubmed: 27056608
Perspect Biol Med. 2018;61(3):388-400
pubmed: 30293977
Psychosom Med. 2011 Feb-Mar;73(2):193-9
pubmed: 21217098
Psychopharmacology (Berl). 2005 Jan;177(3):245-55
pubmed: 15609067
Biol Psychiatry. 2016 May 15;79(10):794-802
pubmed: 26321018
Science. 1962 Nov 9;138(3541):677-8
pubmed: 13954106
Pain. 2001 Jul;93(1):77-84
pubmed: 11406341
Nature. 2016 May 04;533(7604):481-6
pubmed: 27144355
CNS Spectr. 2005 Jun;10(6):440-2
pubmed: 15908896
Addict Behav. 2004 Aug;29(6):1221-4
pubmed: 15236826
Biol Psychiatry. 2016 Sep 15;80(6):448-456
pubmed: 26957131
Handb Exp Pharmacol. 2014;225:291-303
pubmed: 25304538
Int Rev Neurobiol. 2018;138:39-59
pubmed: 29681334
Biol Psychiatry. 2000 Feb 15;47(4):351-4
pubmed: 10686270
Pain. 2016 Aug;157(8):1590-8
pubmed: 27023425
Psychopharmacology (Berl). 2014 Sep;231(18):3663-76
pubmed: 25038867
Neuropharmacology. 2013 Jul;70:27-34
pubmed: 23337256
Nat Neurosci. 2004 Jun;7(6):587-8
pubmed: 15146189
J Neurosci. 1999 Jan 1;19(1):484-94
pubmed: 9870976
Neuroimage. 2017 Feb 15;147:198-203
pubmed: 27986606
FASEB J. 2002 Dec;16(14):1869-73
pubmed: 12468450
Am J Psychiatry. 2006 Nov;163(11):1905-17
pubmed: 17074942
J Pain Res. 2017 Jul 31;10:1831-1839
pubmed: 28831271
Neuropsychopharmacology. 2019 Jun;44(7):1233-1238
pubmed: 30653192
Arch Gen Psychiatry. 1994 Mar;51(3):199-214
pubmed: 8122957
Psychopharmacology (Berl). 2011 Sep;217(1):83-90
pubmed: 21448649
Mol Psychiatry. 2018 Apr;23(4):801-811
pubmed: 29532791
J Psychopharmacol. 2010 Oct;24(10):1561-7
pubmed: 19395430
Neuroscience. 2015 Oct 29;307:171-90
pubmed: 26272535
Evid Based Ment Health. 2010 May;13(2):49
pubmed: 21856612
J Pharmacol Exp Ther. 2015 Oct;355(1):76-85
pubmed: 26265321
J Consult Clin Psychol. 1975 Apr;43(2):278
pubmed: 1120844
J Psychosom Res. 2009 Apr;66(4):323-8
pubmed: 19302890
PLoS Med. 2008 Feb;5(2):e45
pubmed: 18303940
Biol Psychiatry. 2014 Dec 15;76(12):970-6
pubmed: 24821196

Auteurs

Samuel R Krimmel (SR)

Department of Psychiatry, University of Maryland School of Medicine, Baltimore, MD, USA.
Department of Neural and Pain Sciences, University of Maryland School of Dentistry, Baltimore, MD, USA.
Program in Neuroscience, University of Maryland School of Medicine, Baltimore, MD, USA.

Panos Zanos (P)

Department of Psychiatry, University of Maryland School of Medicine, Baltimore, MD, USA.

Polymnia Georgiou (P)

Department of Psychiatry, University of Maryland School of Medicine, Baltimore, MD, USA.

Luana Colloca (L)

Department of Psychiatry, University of Maryland School of Medicine, Baltimore, MD, USA.
Department of Pain Translational Symptom Science, University of Maryland School of Nursing, Baltimore, MD, USA.
Department of Anesthesiology, University of Maryland School of Medicine, Baltimore, MD, USA.
Center to Advance Chronic Pain Research, University of Maryland, Baltimore, USA.

Todd D Gould (TD)

Department of Psychiatry, University of Maryland School of Medicine, Baltimore, MD, USA. gouldlab@me.com.
Department of Pharmacology, University of Maryland School of Medicine, Baltimore, MD, USA. gouldlab@me.com.
Department of Anatomy and Neurobiology, University of Maryland School of Medicine, Baltimore, MD, USA. gouldlab@me.com.
Veterans Affairs Maryland Health Care System, Baltimore, MD, 21201, USA. gouldlab@me.com.

Articles similaires

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male
Humans Meals Time Factors Female Adult

Classifications MeSH